Hypermarcas (OTCMKTS:HYPMY) Trading 7% Higher - What's Next?

Key Points

• Hypermarcas' stock price increased by 7% to $4.28, though trading volume fell by 88% compared to its average.
• Analysts have given Hypermarcas a "strong-buy" rating, indicating positive sentiment towards its future performance.
• The company's recent quarterly earnings report revealed an earnings per share of $0.12, with a net margin of 11.28% and a 6.19% return on equity.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report)'s share price traded up 7% during trading on Tuesday . The stock traded as high as $4.28 and last traded at $4.28. 7,452 shares were traded during trading, a decline of 88% from the average session volume of 63,307 shares. The stock had previously closed at $4.00.

Wall Street Analyst Weigh In

Separately, Scotiabank upgraded shares of Hypermarcas to a "strong-buy" rating in a research note on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Strong Buy".

Hypermarcas Trading Up 7.0%

The company's fifty day moving average price is $4.33 and its two-hundred day moving average price is $4.26. The firm has a market cap of $2.71 billion, a P/E ratio of 20.38 and a beta of 0.83. The company has a current ratio of 1.26, a quick ratio of 0.80 and a debt-to-equity ratio of 0.63.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.12 earnings per share for the quarter. Hypermarcas had a net margin of 11.28% and a return on equity of 6.19%.

About Hypermarcas

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.